Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018 . Following the announcement, Veracyte will host a conference call and webcast
Toggle Summary Veracyte Chairman and CEO to Speak at MedCity CONVERGE
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 2, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson , chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers,


Date Event Details
Summary Toggle Sep 8, 2016 11:00 AM EDT
Veracyte Percepta Medicare Coverage Conference Call
Summary Toggle Nov 29, 2016 3:30 PM EST
Piper Jaffray 28th Annual Healthcare Conference


Title Documents

Veracyte Corporate Presentation, June 2018